Hypoxia inducible factor-1 as a target for neurodegenerative diseases

Current Medicinal Chemistry

Volumn 18, Issue 28, 2011, Pages 4335-4343

  Zhang, Z ^a   Yan, J ^a   Chang, Y ^b   ShiDu Yan, S ^a   Shi, H ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b HEBEI NORMAL UNIVERSITY   (China)

Author keywords

2 oxoglutarate analogues; AD; ALS; Cobalt; EPO; HD; HIF 1; Iron chelator; PD; Prolyl hydroxylase inhbitor; Protein modification; VEGF

Indexed keywords

2 OXOGLUTARIC ACID; CLIOQUINOL; COBALT; COMPOUND HLA20; COMPOUND M30; COMPOUND VK28; DEFEROXAMINE; ERYTHROPOIETIN; FG 0041; HYPOXIA INDUCIBLE FACTOR 1; IRON CHELATING AGENT; PROTOCATECHUIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL ACTIVITY; CELL DAMAGE; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; TISSUE INJURY;

GLUCONATES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IRON CHELATING AGENTS; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 80052929099     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797200426     Document Type: Review

References (112)

1. Shi, H. Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. Curr. Med. Chem., 2009, 16(34), 4593-4600.
2. Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A., 1995, 92(12), 5510-5514.
3. Ke, Q.; Costa, M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol., 2006, 70(5), 1469-1480.
4. Guo, S.; Miyake, M.; Liu, K.J.; Shi, H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J. Neurochem., 2009, 108(5), 1309-1321.
5. Ogunshola, O.O.; Antoniou, X. Contribution of hypoxia to Alzheimer's disease: is HIF-1α a mediator of neurodegeneration? Cell Mol. Life Sci., 2009, 66(22), 3555-3563.
6. Correia, S.C.; Moreira, P.I. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J. Neurochem., 2010, 112(1), 1-12.
7. Gironi, M.; Bianchi, A.; Russo, A.; Alberoni, M.; Ceresa, L.; Angelini, A.; Cursano, C.; Mariani, E.; Nemni, R.; Kullmann, C.; Farina, E.; Martinelli Boneschi, F. Oxidative Imbalance in Different Neurodegenerative Diseases with Memory Impairment. Neurodegener. Dis., 2011, 8(3), 129-37.
8. Benarroch, E.E. Brain iron homeostasis and neurodegenerative disease. Neurology, 2009, 72(16), 1436-1440.
9. Pugh, C.W.; O'Rourke, J.F.; Nagao, M.; Gleadle, J.M.; Ratcliffe, P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J. Biol. Chem., 1997, 272(17), 11205-11214. (Pubitemid 27184117)
10. Ruas, J.L.; Poellinger, L.; Pereira, T. Functional analysis of hypoxiainducible factor-1α-mediated transactivation. Identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein. J. Biol. Chem., 2002, 277(41), 38723-38730. (Pubitemid 35154734)
11. Hewitson, K.S.; McNeill, L.A.; Schofield, C.J. Modulating the hypoxiainducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr. Pharm. Des., 2004, 10(8), 821-833. (Pubitemid 38380061)
12. Srinivas, V.; Zhang, L.P.; Zhu, X.H.; Caro, J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins. Biochem. Biophys. Res. Commun., 1999, 260(2), 557-561. (Pubitemid 29352100)
13. Ivan, M.; Kondo, K.; Yang, H.F.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G. HIF α targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science, 2001, 292(5516), 464-468. (Pubitemid 32335941)
14. Jaakkola, P.; Mole, D.R.; Tian, Y.M.; Wilson, M.I.; Gielbert, J.; Gaskell, S.J.; Kriegsheim, A.; Hebestreit, H.F.; Mukherji, M.; Schofield, C.J.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 2001, 292(5516), 468-472. (Pubitemid 32335942)
15. Maxwell, P.H.; Wiesener, M.S.; Chang, G.W.; Clifford, S.C.; Vaux, E.C.; Cockman, M.E.; Wykoff, C.C.; Pugh, C.W.; Maher, E.R.; Ratcliffe, P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399(6733), 271-275. (Pubitemid 29246458)
16. Ohh, M.; Park, C.W.; Ivan, M.; Hoffman, M.A.; Kim, T.Y.; Huang, L.E.; Pavletich, N.; Chau, V.; Kaelin, W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat. Cell. Biol., 2000, 2(7), 423-427.
17. Salceda, S.; Caro, J. Hypoxia-inducible factor-1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem., 1997, 272(36), 22642-22647. (Pubitemid 27386079)
18. Min, J.H.; Yang, H.; Ivan, M.; Gertler, F.; Kaelin, W.G. Jr.; Pavletich, N.P. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science, 2002, 296(5574), 1886-1889. (Pubitemid 34596278)
19. Weinreb, O.; Amit, T.; Mandel, S.; Kupershmidt, L.; Youdim, M.B. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid. Redox Signal, 2010, 13(6), 919-949.
20. Lando, D.; Peet, D.J.; Whelan, D.A.; Gorman, J.J.; Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science, 2002, 295(5556), 858-861. (Pubitemid 34118367)
21. Jeong, J.W.; Bae, M.K.; Ahn, M.Y.; Kim, S.H.; Sohn, T.K.; Bae, M.H.; Yoo, M.A.; Song, E.J.; Lee, K.J.; Kim, K.W. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell, 2002, 111(5), 709-720. (Pubitemid 35441252)
22. Brahimi-Horn, C.; Mazure, N.; Pouyssegur, J. Signalling via the hypoxiainducible factor-1α requires multiple posttranslational modifications. Cell Signal, 2005, 17(1), 1-9. (Pubitemid 39286774)
23. Gradin, K.; Takasaki, C.; Fujii-Kuriyama, Y.; Sogawa, K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J. Biol. Chem., 2002, 277(26), 23508-23514. (Pubitemid 34952186)
24. Suzuki, H.; Tomida, A.; Tsuruo, T. Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia. Oncogene, 2001, 20(41), 5779-5788. (Pubitemid 32937947)
25. Lancaster, D.E.; McNeill, L.A.; McDonough, M.A.; Aplin, R.T.; Hewitson, K.S.; Pugh, C.W.; Ratcliffe, P.J.; Schofield, C.J. Disruption of dimerization and substrate phosphorylation inhibit factor inhibiting hypoxia-inducible factor (FIH) activity. Biochem. J., 2004, 383(Pt. 3), 429-437. (Pubitemid 39546112)
26. Dimova, E.Y.; Michiels, C.; Kietzmann, T. Kinases as upstream regulators of the HIF system: their emerging potential as anti-cancer drug targets. Curr. Pharm. Des., 2009, 15(33), 3867-3877.
27. Huang, L.E.; Arany, Z.; Livingston, D.M.; Bunn, H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redoxsensitive stabilization of its α subunit. J. Biol. Chem., 1996, 271(50), 32253-32259. (Pubitemid 26422262)
28. Liu, Q.; Berchner-Pfannschmidt, U.; Moller, U.; Brecht, M.; Wotzlaw, C.; Acker, H.; Jungermann, K.; Kietzmann, T. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(12), 4302-4307. (Pubitemid 38405924)
29. Shringarpure, R.; Grune, T.; Mehlhase, J.; Davies, K.J. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem., 2003, 278(1), 311-318. (Pubitemid 36043578)
30. Yasinska, I.M.; Sumbayev, V.V. S-nitrosation of Cys-800 of HIF-1α protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett., 2003, 549(1-3), 105-109. (Pubitemid 36959853)
31. Cho, H.; Ahn, D.R.; Park, H.; Yang, E.G. Modulation of p300 binding by posttranslational modifications of the C-terminal activation domain of hypoxia-inducible factor-1α. FEBS Lett., 2007, 581(8), 1542-1548. (Pubitemid 46528919)
32. Carbia-Nagashima, A.; Gerez, J.; Perez-Castro, C.; Paez-Pereda, M.; Silberstein, S.; Stalla, G.K.; Holsboer, F.; Arzt, E. RSUME, a small RWDcontaining protein, enhances SUMO conjugation and stabilizes HIF-1α during hypoxia. Cell, 2007, 131(2), 309-323. (Pubitemid 47592916)
33. Cheng, J.; Kang, X.; Zhang, S.; Yeh, E.T. SUMO-specific protease 1 is essential for stabilization of hypoxia-inducible factor-1α during hypoxia. Cell, 2007, 131(3), 584-595. (Pubitemid 350007694)
34. Berta, M.A.; Mazure, N.; Hattab, M.; Pouyssegur, J.; Brahimi-Horn, M.C. SUMOylation of hypoxia-inducible factor-1α reduces its transcriptional activity. Biochem. Biophys. Res. Commun., 2007, 360(3), 646-652. (Pubitemid 47048148)
35. Rowland, L.P.; Shneider, N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med., 2001, 344(22), 1688-1700. (Pubitemid 32479968)
36. Vanacore, N.; Cocco, P.; Fadda, D.; Dosemeci, M. Job strain, hypoxia and risk of amyotrophic lateral sclerosis: Results from a death certificate study. Amyotroph. Lateral. Scler., 2010, 11(5), 430-434.
37. Skene, J.P.; Cleveland, D.W. Hypoxia and Lou Gehrig. Nat. Genet., 2001, 28(2), 107-108.
38. Tankersley, C.G.; Haenggeli, C.; Rothstein, J.D. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J. Appl. Physiol., 2007, 102(3), 926-932. (Pubitemid 46377014)
39. Bogaert, E.; Van Damme, P.; Van Den Bosch, L.; Robberecht, W. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve, 2006, 34(4), 391-405. (Pubitemid 44506706)
40. Moreau, C.; Devos, D.; Brunaud-Danel, V.; Defebvre, L.; Perez, T.; Destee, A.; Tonnel, A.B.; Lassalle, P.; Just, N. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry, 2006, 77(2), 255-257. (Pubitemid 43220855)
41. Devos, D.; Moreau, C.; Lassalle, P.; Perez, T.; De Seze, J.; Brunaud-Danel, V.; Destee, A.; Tonnel, A.B.; Just, N. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology, 2004, 62(11), 2127-2129. (Pubitemid 38738240)
42. Oosthuyse, B.; Moons, L.; Storkebaum, E.; Beck, H.; Nuyens, D.; Brusselmans, K.; Van Dorpe, J.; Hellings, P.; Gorselink, M.; Heymans, S.; Theilmeier, G.; Dewerchin, M.; Laudenbach, V.; Vermylen, P.; Raat, H.; Acker, T.; Vleminckx, V.; Van Den Bosch, L.; Cashman, N.; Fujisawa, H.; Drost, M.R.; Sciot, R.; Bruyninckx, F.; Hicklin, D.J.; Ince, C.; Gressens, P.; Lupu, F.; Plate, K.H.; Robberecht, W.; Herbert, J.M.; Collen, D.; Carmeliet, P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet., 2001, 28(2), 131-138. (Pubitemid 32538057)
43. Wang, Y.; Mao, X.O.; Xie, L.; Banwait, S.; Marti, H.H.; Greenberg, D.A.; Jin, K. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci., 2007, 27(2), 304-307. (Pubitemid 46106003)
44. Jin, K.L.; Mao, X.O.; Greenberg, D.A. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(18), 10242-10247.
45. Soker, S.; Takashima, S.; Miao, H.Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoformspecific receptor for vascular endothelial growth factor. Cell, 1998, 92(6), 735-745. (Pubitemid 28155313)
46. Janik, P.; Kwiecinski, H.; Sokolowska, B.; Niebroj-Dobosz, I. Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neural. Transm., 2010, 117(3), 343-347.
47. Chung, Y.H.; Joo, K.M.; Kim, Y.S.; Lee, K.H.; Lee, W.B.; Cha, C.I. Enhanced expression of erythropoietin in the central nervous system of SOD1G93A transgenic mice. Brain Res., 2004, 1016(2), 272-280. (Pubitemid 38887712)
48. Koh, S.H.; Kim, Y.; Kim, H.Y.; Cho, G.W.; Kim, K.S.; Kim, S.H. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur. J. Neurosci., 2007, 25(7), 1923-1930. (Pubitemid 46581743)
49. Grunfeld, J.F.; Barhum, Y.; Blondheim, N.; Rabey, J.M.; Melamed, E.; Offen, D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp. Neurol., 2007, 204(1), 260-263. (Pubitemid 46350729)
50. Kupershmidt, L.; Weinreb, O.; Amit, T.; Mandel, S.; Carri, M.T.; Youdim, M.B. Neuroprotective and neuritogenic activities of novel multimodal ironchelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J., 2009, 23(11), 3766-3779.
51. Bonda, D.J.; Lee, H.G.; Camins, A.; Pallas, M.; Casadesus, G.; Smith, M.A.; Zhu, X. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet. Neurol., 2011, 10(3), 275-279.
52. Di Paolo, G.; Kim, T.W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci., 2011, 12(5), 284-296.
53. Tanzi, R.E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 2005, 120(4), 545-555. (Pubitemid 40269768)
54. Palmer, A.M. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends. Pharmacol. Sci., 2011, 32(3), 141-147.
55. Selkoe, D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J. Alzheimers Dis., 2001, 3(1), 75-80.
56. Moreira, P.I.; Honda, K.; Zhu, X.; Nunomura, A.; Casadesus, G.; Smith, M.A.; Perry, G. Brain and brawn: parallels in oxidative strength. Neurology, 2006, 66(2 Suppl 1), S97-101. (Pubitemid 43739993)
57. Avramovich-Tirosh, Y.; Bar-Am, O.; Amit, T.; Youdim, M.B.; Weinreb, O. Up-regulation of hypoxia-inducible factor (HIF) -1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res., 2010, 7(4), 300-306.
58. Soucek, T.; Cumming, R.; Dargusch, R.; Maher, P.; Schubert, D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid β peptide. Neuron, 2003, 39(1), 43-56. (Pubitemid 36830947)
59. Crapper McLachlan, D.R.; Dalton, A.J.; Kruck, T.P.; Bell, M.Y.; Smith, W.L.; Kalow, W.; Andrews, D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet, 1991, 337(8753), 1304-1308.
60. Bell, R.D.; Zlokovic, B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta. Neuropathol., 2009, 118(1), 103-113.
61. Hoyer, S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv. Exp. Med. Biol., 2004, 541, 135-152. (Pubitemid 38037371)
62. Taupin, P. A dual activity of ROS and oxidative stress on adult neurogenesis and Alzheimer's disease. Cent. Nerv. Syst. Agents Med. Chem., 2010, 10(1), 16-21.
63. Desmond, D.W.; Moroney, J.T.; Sano, M.; Stern, Y. Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke, 2002, 33(9), 2254-2260. (Pubitemid 35014639)
64. Fleisher, A.S.; Podraza, K.M.; Bangen, K.J.; Taylor, C.; Sherzai, A.; Sidhar, K.; Liu, T.T.; Dale, A.M.; Buxton, R.B. Cerebral perfusion and oxygenation differences in Alzheimer's disease risk. Neurobiol. Aging, 2009, 30(11), 1737-1748.
65. Egashira, N.; Iwasaki, K.; Ishibashi, M.; Hatip-Al-Khatib, I.; Wolozin, B.; Mishima, K.; Irie, K.; Fujiwara, M. Hypoxia enhances β-amyloid-induced apoptosis in rat cultured hippocampal neurons. Jpn. J. Pharmacol., 2002, 90(4), 321-327.
66. Vu, K.; Weksler, B.; Romero, I.; Couraud, P.O.; Gelli, A. Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans. Eukaryot. Cell, 2009, 8(11), 1803-1807.
67. Liu, Y.; Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Gong, C.X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett., 2008, 582(2), 359-364.
68. Maiese, K.; Chong, Z.Z.; Li, F.; Shang, Y.C. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog. Neurobiol., 2008, 85(2), 194-213.
69. Storkebaum, E.; Lambrechts, D.; Carmeliet, P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays, 2004, 26(9), 943-954. (Pubitemid 39273068)
70. Chong, Z.Z.; Li, F.; Maiese, K. Erythropoietin requires NF-αB and its nuclear translocation to prevent early and late apoptotic neuronal injury during α-amyloid toxicity. Curr Neurovasc. Res., 2005, 2(5), 387-399. (Pubitemid 41789605)
71. Mala, H.; Alsina, C.G.; Madsen, K.S.; Sibbesen, E.C.; Stick, H.; Mogensen, J. Erythropoietin improves place learning in an 8-arm radial maze in fimbriafornix transected rats. Neural. Plast., 2005, 12(4), 329-340. (Pubitemid 43072008)
72. Nakagawa, T.; Zhu, H.; Morishima, N.; Li, E.; Xu, J.; Yankner, B.A.; Yuan, J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature, 2000, 403(6765), 98-103. (Pubitemid 30038529)
73. Perry, V.H.; Nicoll, J.A.; Holmes, C. Microglia in neurodegenerative disease. Nat. Rev. Neurol., 2010, 6(4), 193-201.
74. Zhou, J.; Dehne, N.; Brune, B. Nitric oxide causes macrophage migration via the HIF-1-stimulated small GTPases Cdc42 and Rac1. Free Radic. Biol. Med., 2009, 47(6), 741-749.
75. Sullivan, A.M.; Toulouse, A. Neurotrophic factors for the treatment of Parkinson's disease. Cytokine Growth Factor Rev., 2011. doi:10.1016/j.cytogfr. 2011.05.001.
76. Meissner, W.G.; Frasier, M.; Gasser, T.; Goetz, C.G.; Lozano, A.; Piccini, P.; Obeso, J.A.; Rascol, O.; Schapira, A.; Voon, V.; Weiner, D.M.; Tison, F.; Bezard, E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov., 2011, 10(5), 377-393.
77. Fujita, K.; Nakabeppu, Y.; Noda, M. Therapeutic effects of hydrogen in animal models of Parkinson's disease. Parkinsons Dis., 2011, 2011, 307875.
78. Cohen, G.; Farooqui, R.; Kesler, N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U. S. A., 1997, 94(10), 4890-4894. (Pubitemid 27214706)
79. Haavik, J. L-DOPA is a substrate for tyrosine hydroxylase. J. Neurochem., 1997, 69(4), 1720-1728. (Pubitemid 27406973)
80. Agani, F.H.; Pichiule, P.; Chavez, J.C.; LaManna, J.C. The role of mitochondria in the regulation of hypoxia-inducible factor-1 expression during hypoxia. J. Biol. Chem., 2000, 275(46), 35863-35867.
81. Haavik, J.; Toska, K. Tyrosine hydroxylase and Parkinson's disease. Mol. Neurobiol., 1998, 16(3), 285-309. (Pubitemid 28268547)
82. Millhorn, D.E.; Raymond, R.; Conforti, L.; Zhu, W.; Beitner-Johnson, D.; Filisko, T.; Genter, M.B.; Kobayashi, S.; Peng, M. Regulation of gene expression for tyrosine hydroxylase in oxygen sensitive cells by hypoxia. Kidney Int., 1997, 51(2), 527-535. (Pubitemid 27088170)
83. Schnell, P.O.; Ignacak, M.L.; Bauer, A.L.; Striet, J.B.; Paulding, W.R.; Czyzyk-Krzeska, M.F. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J. Neurochem., 2003, 85(2), 483-491. (Pubitemid 36438344)
84. Czyzyk-Krzeska, M.F.; Furnari, B.A.; Lawson, E.E.; Millhorn, D.E. Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells. J. Biol. Chem., 1994, 269(1), 760-764. (Pubitemid 24026725)
85. Nguyen, M.V.; Pouvreau, S.; El Hajjaji, F.Z.; Denavit-Saubie, M.; Pequignot, J.M. Desferrioxamine enhances hypoxic ventilatory response and induces tyrosine hydroxylase gene expression in the rat brainstem in vivo. J. Neurosci. Res., 2007, 85(5), 1119-1125. (Pubitemid 46580353)
86. Milosevic, J.; Maisel, M.; Wegner, F.; Leuchtenberger, J.; Wenger, R.H.; Gerlach, M.; Storch, A.; Schwarz, J. Lack of hypoxia-inducible factor-1α impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. J. Neurosci., 2007, 27(2), 412-421. (Pubitemid 46106015)
87. Witten, L.; Sager, T.; Thirstrup, K.; Johansen, J.L.; Larsen, D.B.; Montezinho, L.P.; Mork, A. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J. Neurosci. Res., 2009, 87(7), 1686-1694.
88. Lee, D.W.; Rajagopalan, S.; Siddiq, A.; Gwiazda, R.; Yang, L.; Beal, M.F.; Ratan, R.R.; Andersen, J.K. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J. Biol. Chem., 2009, 284(42), 29065-29076.
89. Lan, J.; Jiang, D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm., 1997, 104(4-5), 469-481. (Pubitemid 27379903)
90. Ben-Shachar, D.; Eshel, G.; Finberg, J.P.; Youdim, M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem., 1991, 56(4), 1441-1444. (Pubitemid 21902069)
91. Signore, A.P.; Weng, Z.; Hastings, T.; Van Laar, A.D.; Liang, Q.; Lee, Y.J.; Chen, J. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J. Neurochem., 2006, 96(2), 428-443.
92. Silverman, W.F.; Krum, J.M.; Mani, N.; Rosenstein, J.M. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience, 1999, 90(4), 1529-1541. (Pubitemid 29170166)
93. Cummins, A.; Eggert, J.; Pruitt, R.; Collins, J.S. Huntington disease: Implications for practice. Nurse Pract., 2011, 36(2), 41-47.
94. Crook, Z.R.; Housman, D. Huntington's disease: can mice lead the way to treatment? Neuron, 2011, 69(3), 423-435.
95. Quintanilla, R.A.; Jin, Y.N.; Fuenzalida, K.; Bronfman, M.; Johnson, G.V. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferatoractivated receptor-α (PPARα) in the pathogenesis of Huntington disease. J. Biol. Chem., 2008, 283(37), 25628-25637.
96. Jin, Y.N.; Johnson, G.V. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr., 2010, 42(3), 199-205.
97. Hsiao, H.Y.; Chern, Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol. Neurobiol., 2010, 41(2-3), 248-255.
98. Estrada Sanchez, A.M.; Mejia-Toiber, J.; Massieu, L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch. Med. Res., 2008, 39(3), 265-276. (Pubitemid 351221151)
99. Shin, J.Y.; Fang, Z.H.; Yu, Z.X.; Wang, C.E.; Li, S.H.; Li, X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell. Biol., 2005, 171(6), 1001-1012.
100. Lievens, J.C.; Woodman, B.; Mahal, A.; Spasic-Boscovic, O.; Samuel, D.; Kerkerian-Le Goff, L.; Bates, G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis., 2001, 8(5), 807-821. (Pubitemid 33055597)
101. Nguyen, T.; Hamby, A.; Massa, S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(33), 11840-11845. (Pubitemid 41170812)
102. Yang, Y.T.; Ju, T.C.; Yang, D.I. Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. J. Neurochem., 2005, 93(3), 513-525.
103. Brand, K.A.; Hermfisse, U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J., 1997, 11(5), 388-395. (Pubitemid 27193945)
104. Niatsetskaya, Z.; Basso, M.; Speer, R.E.; McConoughey, S.J.; Coppola, G.; Ma, T.C.; Ratan, R.R. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid. Redox. Signal., 2010, 12(4), 435-443.
105. Hewitson, K.S.; Schofield, C.J. The HIF pathway as a therapeutic target. Drug Discov. Today, 2004, 9(16), 704-711. (Pubitemid 39070283)
106. Weinreb, O.; Mandel, S.; Bar-Am, O.; Amit, T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J. Neural. Transm., 2011, 118(3), 479-492.
107. Whitnall, M.; Richardson, D.R. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol., 2006, 13(3), 186-197. (Pubitemid 44709656)
108. Thirstrup, K.; Christensen, S.; Moller, H.A.; Ritzen, A.; Bergstrom, A.L.; Sager, T.N.; Jensen, H.S. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. Pharmacol. Res., 2011, 64(3), 268-273.
109. Masson, N.; Ratcliffe, P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels. J. Cell. Sci., 2003, 116(Pt 15), 3041-3049. (Pubitemid 37038953)
110. Groulx, I.; Lee, S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol., 2002, 22(15), 5319-5336. (Pubitemid 34755745)
111. Hewitson, K.S.; McNeill, L.A.; Riordan, M.V.; Tian, Y.M.; Bullock, A.N.; Welford, R.W.; Elkins, J.M.; Oldham, N.J.; Bhattacharya, S.; Gleadle, J.M.; Ratcliffe, P.J.; Pugh, C.W.; Schofield, C.J. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem., 2002, 277(29), 26351-26355. (Pubitemid 34967127)
112. Bae, S.H.; Jeong, J.W.; Park, J.A.; Kim, S.H.; Bae, M.K.; Choi, S.J.; Kim, K.W. Sumoylation increases HIF-1α stability and its transcriptional activity. Biochem. Biophys. Res. Commun., 2004, 324(1), 394-400. (Pubitemid 39311508)